Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, Stegmaier K.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9751-6. doi: 10.1073/pnas.0710413105. Epub 2008 Jul 7.

2.

The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.

Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP.

Cancer Res. 2001 May 1;61(9):3591-4.

3.

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R.

Mol Cancer Ther. 2007 Jan;6(1):70-81.

4.

Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.

Lautz TB, Naiditch JA, Clark S, Chu F, Madonna MB.

J Pediatr Surg. 2012 Jun;47(6):1267-71. doi: 10.1016/j.jpedsurg.2012.03.039.

PMID:
22703804
5.

Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells.

De los Santos M, Zambrano A, Aranda A.

Mol Cancer Ther. 2007 Apr;6(4):1425-32.

6.

p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.

Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, Guerra F, Pession A, Ferreri AM.

Oncol Rep. 2005 Jun;13(6):1139-44.

PMID:
15870934
7.

Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.

Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL.

Cancer Res. 2007 Feb 15;67(4):1716-24.

8.

Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.

Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, Iraci N, Sekyere E, Haber M, Norris MD, Diolaiti D, Della Valle G, Perini G, Marshall GM.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18682-7. Epub 2007 Nov 14. Erratum in: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):21021.

9.

The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.

de Ruijter AJ, Kemp S, Kramer G, Meinsma RJ, Kaufmann JO, Caron HN, van Kuilenburg AB.

Biochem Pharmacol. 2004 Oct 1;68(7):1279-88.

PMID:
15345317
10.

Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma.

de Ruijter AJ, Meinsma RJ, Bosma P, Kemp S, Caron HN, van Kuilenburg AB.

Exp Cell Res. 2005 Oct 1;309(2):451-67.

PMID:
16084510
11.

Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.

Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP.

Cancer Res. 1999 Sep 1;59(17):4392-9.

12.

In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.

Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R.

Prostate. 2005 Jun 15;64(1):20-8.

PMID:
15651062
13.

Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs.

Lovat PE, Ranalli M, Bernassola F, Tilby M, Malcolm AJ, Pearson AD, Piacentini M, Melino G, Redfern CP.

Int J Cancer. 2000 Dec 15;88(6):977-85.

14.

Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.

Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, Roti G, Kung AL, Bradner JE, Tolliday N, Stegmaier K.

Chem Biol. 2013 May 23;20(5):713-25. doi: 10.1016/j.chembiol.2013.03.020.

16.

HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.

Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, Witt O.

Anticancer Drugs. 2008 Oct;19(9):849-57. doi: 10.1097/CAD.0b013e32830efbeb.

PMID:
18765999
17.

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.

Carew JS, Giles FJ, Nawrocki ST.

Cancer Lett. 2008 Sep 28;269(1):7-17. doi: 10.1016/j.canlet.2008.03.037. Epub 2008 May 6. Review.

PMID:
18462867
18.
19.

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA.

Clin Cancer Res. 2001 Apr;7(4):962-70.

Supplemental Content

Support Center